GLP-1 boom puts medispas under regulatory scrutiny, insurance pressure
The surge in demand for GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has transformed medispas from cosmetic and wellness hubs into key players in weight-loss treatment, drawing significant regulatory and insurance scrutiny. As of August 19, 2025, recent developments highlight the challenges medispas face: Regulatory Scrutiny: The FDA resolved shortages of semaglutide … Read more